March 13, 2019

BD's Covera Vascular Stent Approved for Patients With End-Stage Renal Disease

March 14, 2019—BD (Becton, Dickinson and Company) has received FDA premarket approval of the Covera vascular covered stent for patients with end-stage renal disease who are on hemodialysis.

According to the company, the Covera device is approved in the United States for use in the treatment of stenoses in native (nonstented) fistulae. Covera was designed to address challenging lesions in the arteriovenous access circuit. It is available in both a flared and a straight configuration to allow for precise sizing and apposition to the vessel wall, and it includes an easy-to-use thumbwheel delivery system.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

March 13, 2019

BD's Covera Vascular Stent Approved for Patients With End-Stage Renal Disease

Current Issue

Keep In Touch